Record Q3 Revenue
Covalon Reports Record Q3 Revenue and Strong Profitability on Growing Hospital Adoption
Anonymous
Key Points
1
Nine-month results for Covalon in fiscal 2026 show revenue of CAD 25.66 million, net income of CAD 4.03 million, and basic/diluted earnings per share of CAD 0.15 for the period ended June 30, 2026.
2
Covalon’s fiscal Q3 2026 was described as the strongest quarterly performance in five years, with the company ending the quarter with about USD 19.4 million in cash and no bank debt (cash balance up USD 2.8 million from the prior quarter).
3
Contamination Protection revenue rose 34% quarter-over-quarter in the fiscal 2026 third quarter, signaling ongoing momentum in Covalon’s infection-prevention portfolio.
4
The US Vascular Access and Surgical Consumables segment grew 51% year over year in Q3 2026, a step above the overall market growth and a key driver of Covalon’s quarterly performance.
Covalon reported its strongest quarterly performance in five years, with Q3 fiscal 2026 revenue of CAD 10.04 million, up 20% year over year. The medical device maker swung to profitability with net income of CAD 2.81 million and earnings per share of CAD 0.15, while gross margins expanded sharply to 67.2%, MarketScreener reported. The company ended the quarter debt-free with CAD 19.4 million in cash.
Contamination Protection Drives Explosive Growth
Covalon's Contamination Protection line powered the quarter's gains, rising 68% year over year and accounting for the bulk of revenue growth. The segment grew 34% sequentially from the prior quarter, signaling sustained momentum in infection-prevention products. Investing.com noted that margins on the contamination line surged 2,070 basis points, the primary driver of profitability expansion.
Vascular Access Segment Outpaces Market Growth
The US Vascular Access and Surgical Consumables segment delivered the strongest segment performance, growing 51% year over year in Q3. This growth rate significantly exceeded broader market expansion, positioning it as Covalon's primary growth engine. The segment's outperformance reflects accelerating hospital adoption of the company's product portfolio across all sales channels.
Adjusted EBITDA Triples on Operating Leverage
Adjusted EBITDA reached approximately CAD 3.0 million, more than triple the prior-year quarter. This expansion demonstrates the scalability of Covalon's business model as revenues grow and manufacturing spreads fixed costs across higher output. Management highlighted the result as proof of concept for the company's path to sustained profitability and broader commercial scale.
Fortress Balance Sheet Fuels Growth Ambitions
Covalon's cash position strengthened to CAD 19.4 million with zero bank debt, up CAD 2.8 million from the prior quarter. The fortress balance sheet provides ammunition for product development, market expansion, and potential acquisitions without reliance on external financing. WatchlistNews reported the company beat earnings estimates by CAD 0.05 per share, reinforcing investor confidence in management's execution.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
25
Reach
35
Topics
A
AnonymousAuthor
